RJFSA
ARQT icon

Raymond James Financial Services Advisors’s Arcutis Biotherapeutics ARQT Stock Holding History

Raymond James Financial Services Advisors’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-10,675
Closed -$106K – 3406
2024
Q1 		$106K Buy
+10,675
New +$79.7K ﹤0.01% 3218

Other funds holding ARQT

Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Raymond James Financial Services Advisors's ARQT Position: Q2 2024 in Review

Raymond James Financial Services Advisors sold out of Arcutis Biotherapeutics (ARQT) in Q2 2024, closing a stake of 10,675 shares — an estimated $106K sold.

Raymond James Financial Services Advisors first reported a position in ARQT in Q1 2024 and held it in 1 quarter. The position peaked at $106K in Q1 2024. 186 funds tracked by Wall St. Rank hold ARQT as of Q2 2024.

  • Raymond James Financial Services Advisors reported no remaining Arcutis Biotherapeutics position as of Q2 2024 after selling out during the quarter.
  • Raymond James Financial Services Advisors sold 10,675 Arcutis Biotherapeutics shares in Q2 2024, an estimated $106K.
  • Raymond James Financial Services Advisors first reported a position in Arcutis Biotherapeutics in Q1 2024 and held it in 1 quarter.
  • Raymond James Financial Services Advisors's Arcutis Biotherapeutics position peaked at $106K in Q1 2024.
  • 186 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2024.

Based on Raymond James Financial Services Advisors's 13F filing for Q2 2024, filed 19 Jul 2024.